source
- Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD programNovo Nordisk reported that its phase 3 Zeus trial of the IL‑6 ligand antibody ziltivekimab did not meet its primary endpoint, a setback for the drug's development. The study enrolled more than 6,3…
- Biogen CEO says company will pause new acquisitions and focus on developing existing pipelineBiogen's chief executive Christopher Viehbacher told analysts during the second-quarter earnings call that the company will slow its merger and acquisition activity for the foreseeable future. Aft…